Glutaric acid derivatives and preparation thereof
    5.
    发明授权
    Glutaric acid derivatives and preparation thereof 失效
    戊二酸衍生物及其制备方法

    公开(公告)号:US5157138A

    公开(公告)日:1992-10-20

    申请号:US757853

    申请日:1991-09-11

    IPC分类号: C07C229/46

    CPC分类号: C07C229/46 C07C2101/08

    摘要: The invention provides the substantially optically pure 2(S)-steroisomeric form of compounds of the formulae: ##STR1## and the salts thereof, together with processes for their preparation. The compounds are intermediates for the preparation of antihypertensive agents.

    摘要翻译: 本发明提供基本上光学上纯的2(S) - 异构体形式的下式化合物及其盐,以及其制备方法:其中式(I)和(II)化合物及其盐。 该化合物是制备抗高血压药物的中间体。

    Glutaric acid derivatives and preparation thereof
    6.
    发明授权
    Glutaric acid derivatives and preparation thereof 失效
    戊二酸衍生物及其制备方法

    公开(公告)号:US5260467A

    公开(公告)日:1993-11-09

    申请号:US28854

    申请日:1993-03-10

    CPC分类号: C07C229/46 C07C2101/08

    摘要: The invention provides the substantially optically pure 2(S)-stereoisomeric form of compounds of the formulae: ##STR1## and the salts thereof, together with processes for their preparation. The compounds are intermediates for the preparation of antihypertensive agents.

    摘要翻译: 本发明提供基本上光学上纯的2(S) - 立体异构形式的下式化合物及其盐,以及其制备方法:其中式(I)和(II)化合物及其盐。 该化合物是制备抗高血压药物的中间体。

    Cycloalkyl-substituted glutaramide antihypertensive agents
    8.
    发明授权
    Cycloalkyl-substituted glutaramide antihypertensive agents 失效
    环烷基取代戊二酰胺抗高血压药

    公开(公告)号:US4975444A

    公开(公告)日:1990-12-04

    申请号:US398675

    申请日:1989-08-25

    摘要: Compounds of the formula ##STR1## wherein A is a carbocyclic, saturated or unsaturated ring; R.sup.1 is hydrogen or alkyl; R and R.sup.4 are each alkyl, cycloalkyl, benzyl or a readily hydrolyzable ester group; Y is a bond or a straight or branch alkylene; R.sup.2 is hydrogen, aryl, heterocyclic, R.sup.6 CONR.sup.5, R.sup.7 NR.sup.5 CO, R.sup.7 NR.sup.5 SO.sub.2 --or R.sup.8 SO.sub.2 NR.sup.5 --where R.sup.5 is hydrogen, alkyl or aralkyl; R.sup.6 is alkyl, aryl, aralkyl, heterocyclic, heterocyclyalkyl or a group of the formula ##STR2## where R.sup.9 is hydrogen, hydroxy, alkoxy, alkyl, hydroxyalkyl, aralkyl, alkylene, heterocyclic, heterocyclylalkyl, R.sup.12 CONH--, R.sup.12 SO.sub.2 NH-- or (R.sup.13).sub.2 N--; R.sup.10 and R.sup.11 are each hydrogen or alkyl; or R.sup.10 is hydrogen and R.sup.11 is aminoalkyl, imidazolylmethyl, aryl, aralkyl, aralkoxyalkoxy, hydroxyalkyl or methylthioalkyl; or R.sup.10 and R.sup.11 together with the carbon to which they are attached form a carbocyclic or heterocyclic ring optionally substituted by amino, alkanoyl or aroyl; R.sup.12 is alkyl, cycloalkyl, aryl, aralkyl, heterocyclic or heterocyclylalkyl; each R.sup.13 is hydrogen, alkyl, aralkyl or both R.sup.13 together with the nitrogen to which they are attached form a heterocyclic ring; R.sup.7 is alkyl, aryl, aralkyl, heterocyclic, heterocyclyalkyl or a group ##STR3## where R.sup.10 and R.sup.11 are as defined and R.sup.14 is (R.sup.13).sub.2 NCO, R.sup.12 OCH.sub.2 -- or R.sup.15 OCO, where R.sup.12 and R.sup.13 are as defined and R.sup.15 is alkyl, cycloalkyl or aralkyl; and R.sup.8 is alkyl, aryl, aralkyl, heterocyclic or heterocyclylalkyl; R.sup.3 is a group ##STR4## where R.sup.16 is hydrogen, halo, hydroxy, alkoxy, cycloalkoxy, alkenyloxy, alkoxycarbonyloxy, cycloalkoxycarbonylalkoxy or alkyl SO.sub.2 NH--; and R.sup.20 is hydrogen, alkyl, alkoxy, alkanoyl or halo; or R.sup.3 is 3-indolylmethyl or 3-indazolylmethyl, each optionally substituted in the benzenoid ring by alkyl, alkoxy, hydroxy or trifluoromethyl as antihypertensive agents.

    摘要翻译: 其中A是碳环,饱和或不饱和环的式IMA的化合物; R1是氢或烷基; R和R4各自为烷基,环烷基,苄基或易水解的酯基; Y是一个键或直链或支链亚烷基; R2是氢,芳基,杂环,R6CONR5,R7NR5CO,R7NR5SO2或R8SO2NR5,其中R5是氢,烷基或芳烷基; 其中R 9是氢,羟基,烷氧基,烷基,羟基烷基,芳烷基,亚烷基,杂环基,杂环基烷基,R 12 CONH-,R 12 SO 2 NH-或(R 13) 2N-; R 10和R 11各自为氢或烷基; 或R 10为氢,R 11为氨基烷基,咪唑基甲基,芳基,芳烷基,芳烷氧基烷氧基,羟基烷基或甲硫基烷基; 或R 10和R 11与它们所连接的碳一起形成任选被氨基,烷酰基或芳酰基取代的碳环或杂环; R 12是烷基,环烷基,芳基,芳烷基,杂环或杂环基烷基; 每个R 13是氢,烷基,芳烷基或两者R 13与它们所连接的氮一起形成杂环; R 7是烷基,芳基,芳烷基,杂环基,杂环烷基或基团,其中R 10和R 11如上所定义,R 14是(R 13)2 COCO,R 12 OCH 2或R 15 OCO,其中R 12和R 13如上定义,R 15是烷基,环烷基 或芳烷基; R8是烷基,芳基,芳烷基,杂环或杂环基烷基; R3是一个基团,其中R16是氢,卤素,羟基,烷氧基,环烷氧基,烯氧基,烷氧基羰氧基,环烷氧基羰基烷氧基或烷基SO2NH-; 和R 20是氢,烷基,烷氧基,烷酰基或卤素; 或R3是3-吲哚基甲基或3-吲唑基甲基,其各自任选在苯环中被烷基,烷氧基,羟基或三氟甲基取代作为抗高血压剂。

    Method of encapsulating organic material
    10.
    发明授权
    Method of encapsulating organic material 失效
    封装有机材料的方法

    公开(公告)号:US4812242A

    公开(公告)日:1989-03-14

    申请号:US88990

    申请日:1987-08-21

    摘要: Organic material, particularly organic material floating on a water surface, can be encapsulated by reacting, in the presence of the organic material, (A) a functionalized liquid polymer containing anhydride functional groups which groups are derived from an alpha, beta-ethylenically unsaturated dicarboxylic acid anhydride and (B) an alkoxylated fatty monoamine or polyamine having from 1.5 to 15 moles of alkoxylate per mole of fatty amine. The functionalized polymer (A) may be, for example, maleinized polybutadiene and the alkoxylated fatty amine may be, for example, N,N.sup.1, N.sup.1 -tris (2-hydroxypropyl)-N-oleyl-1,3-diaminopropane. Preferably, the alkoxylated fatty amine is derived from a fatty amine having an iodine value of at least 65. The method may also be used to encapsulate a solid contaminated with organic material e.g. oil drilling cuttings.

    摘要翻译: 有机材料,特别是漂浮在水表面上的有机材料可以通过在有机材料存在下使(A)含有酸酐官能团的官能化液体聚合物反应来包封,该基团衍生自α,β-烯键式不饱和二羧酸 酸酐和(B)每摩尔脂肪胺具有1.5至15摩尔烷氧基化物的烷氧基化脂肪单胺或多胺。 官能化聚合物(A)可以是例如马来化聚丁二烯,烷氧基化脂肪胺可以是例如N,N 1,N 3 - 三(2-羟丙基)-N-油基-1,3-二氨基丙烷。 优选地,烷氧基化脂肪胺衍生自碘值至少为65的脂肪胺。该方法还可用于包封被有机材料污染的固体,例如, 石油钻采。